Neurological disorders present a variety of challenges, from screening people who may have a specific disorder to monitoring patients at home. Digital Health Accelerator Program PharmStars graduate A group of startups that are developing potential new solutions.
PharmStars focuses on mentoring startups using digital technologies to solve some of the challenges or problems facing the pharmaceutical industry. Each batch of startups is formed around a specific theme. Innovation in neurological diseases was the subject of a recent group of accelerator participants.
Startups belonging to PharmStars participate in a 10-week program. Courses teach them about the pharmaceutical industry. Participants also have the opportunity to meet with representatives of large pharmaceutical companies who provide guidance. These pharma companies don’t select startups for each cohort, but they provide input on topics. Pharmaceutical company members of the accelerator include Takeda, Novo Nordisk, Eli Lilly and Boehringer Ingelheim.
PharmStars is still accepting applications for its program this fall. New Topic: Innovation in Real World Evidence.More information and application forms are available on PharmStars website. The application deadline is July 16.
Here are the 11 digital health startups that completed the PharmStars spring program:
acceptable. Assessing speech is a method of screening and monitoring for neurodegenerative diseases. Barcelona-based Accexible is developing device-independent speech biomarkers for mild cognitive impairment and early dementia.
caring linkThe Lamson, N.J.-based company is developing a gamified mobile app that uses artificial intelligence to assess neurological function and decline.
intentional artificial intelligenceDeliberate’s technology, based in New York, is a multimodal diagnostic platform and machine learning model for analyzing behavioral and physiological biomarkers to detect symptoms and monitor patients with psychiatric and neurological disorders.
head diagnosisThe Dublin-based company is developing a technology that can measure nystagmus, an indicator of Parkinson’s disease. The company’s handheld device is designed to enable rapid and non-invasive assessment of disease.
HealthQb TechnologyVancouver, British Columbia-based HealthQb is developing what it describes as a biopsychosocial behavior modification system for pain and chronic conditions. The company says the technology is designed to objectively measure, prioritize and personalize patients’ “hidden” psychosocial factors that contribute to their ongoing illness.
pattern healthWearables startup Modus Health’s technology is the StepWatch, a medical device that performs a real-world assessment of a person’s movement. The Edmonds, Washington-based device has potential applications in clinical care, clinical trials and research applications.
NeurovirusBrussels-based Neuroventis is developing a software platform to help patients with neurological disorders understand and manage their disease, while also enabling them to better interact with clinicians.
Orbit HealthThe Munich-based startup’s artificial intelligence technology uses commercially available smartwatches to provide information about real-world motor symptoms and response to treatment in Parkinson’s disease patients.
Reactive nerves. REACT’s home-based virtual reality platform, located in Cambridge, Massachusetts, provides quantitative, comprehensive, and objective neurocognitive assessments.
Vistim Labs. Salt Lake City-based Vistim technology uses AI to assess brain activity, obtaining an objective measure of previously undetectable changes in cognitive function.
WKD. Death. Cambridge-based startup WKD.SMRT is developing a video and sensor technology for the home that passively and continuously collects data on a person’s movement and functional performance.
Image: mrspopman, Getty Images
